FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Procaps Group, S.A. Stock AnalysisComprehensive stock analysis for Procaps Group, S.A. (PROCW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPROCW
PROCW
Procaps Group, S.A.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
PROCW
Home🔹Stocks🔹Procaps Group, S.A.

Procaps Group, S.A.

PROCW•NASDAQ

Procaps Group, S.A.

PROCW•NASDAQ
Market cap
$1.96M
Sentiment

Your view on PROCW

Mkt Cap
$1.96M
Sentiment
Your view
PROCW
Procaps Group, S.A.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
PROCW
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Procaps Group, S.A.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Jose Antonio Toledo Vieira
Headquarters
9 rue de Bitbourg, Luxembourg City, LU
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Jose Antonio Toledo Vieira
Headquarters
9 rue de Bitbourg, Luxembourg City, LU
Description

Procaps Group, S.A. operates as a globally integrated healthcare and pharmaceutical enterprise. The company is actively involved in the development, production, and distribution of branded prescription medications across numerous therapeutic domains, including women's health, pain management, dermatology, digestive wellness, growth and development, cardiovascular health, ophthalmology, central nervous system disorders, and respiratory ailments. Additionally, it supplies a range of pharmaceuticals for hospital use, such as antibiotics, anticoagulants, personal protective equipment, immunosuppressants, oncology treatments, and analgesics. Procaps also offers an extensive portfolio of over-the-counter (OTC) consumer healthcare products, covering approximately ten distinct therapeutic categories. These include gastrointestinal health, skincare, cough and cold remedies, pain relief, urological support, and various vitamins, minerals, and dietary supplements. Further specialized areas encompass anti-infective agents, cardiovascular medications, feminine care products, cutaneous antimycotics, hormonal treatments, metabolic and endocrine solutions, nervous system drugs, ophthalmic preparations, osteoarticular therapies, and respiratory aids. Beyond its core pharmaceutical offerings, the company provides comprehensive diabetes management solutions, including blood glucose meters, telemonitoring systems, oral antidiabetics, and insulin delivery devices, alongside cosmeceuticals and other related products. Furthermore, Procaps extends its capabilities to third-party pharmaceutical companies by offering contract drug development and manufacturing services, with a specific expertise in soft gelatin capsule technologies. Founded in 1977, the company is headquartered in Luxembourg City, Luxembourg.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

FRC's fair value estimate for Procaps Group, S.A., and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Procaps Group, S.A.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Procaps Group, S.A.. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Procaps Group, S.A.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Procaps Group, S.A.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Procaps Group, S.A. valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Which institutions hold Procaps Group, S.A., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

Buying and selling by Procaps Group, S.A. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Procaps Group, S.A.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Procaps Group, S.A.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Procaps Group, S.A.. Press releases and market coverage, newest first.

News

Latest Market News